

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/CAplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:41:29 ON 22 OCT 2007

=> file registry
COST IN U.S. DOLLARS

| SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|
| 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 13:42:11 ON 22 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2007 HIGHEST RN 951118-42-6
DICTIONARY FILE UPDATES: 19 OCT 2007 HIGHEST RN 951118-42-6

New CAS Information Use Policies, enter **HELP USAGETERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10583335\10583335a.str



chain nodes :

10 17 18 19 26 27 28 29 31

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 20 21 22 23 24 25

chain bonds

2-11 4-10

ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
 15-16 20-21 20-25 21-22 22-23 23-24 24-25

15-16 20-21 20-
exact/norm bonds

exact/norm bonds : .
1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-28 8-9 9-27 13-17 16-26
17-18 17-19 17-20 20-21 20-25 21-22 22-23 23-24 23-29 24-25 26-31

exact bonds :

2-11

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16

G1:H,Ak,Cb

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS
29:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:43:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 89 TO ITERATE

100.0% PROCESSED 89 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1214 TO 2346

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:43:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1639 TO ITERATE


100.0% PROCESSED 1639 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.01

L3 25 SEA SSS FUL L1

=> d scan

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Piperazine, 1-[(3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxypyhenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-
 (9CI)
 MF C25 H36 N6 O3 S2

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Piperazine, 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxypyhenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-
 (9CI)
 MF C24 H34 N6 O3 S2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Piperazine, 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-
 (9CI)
 MF C23 H32 N6 O3 S2
 CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Piperazine, 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl)sulfonyl]-4-ethyl- (9CI)
 MF C26 H38 N6 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| | 173.00 | 173.21 |

FILE 'CAPLUS' ENTERED AT 13:43:52 ON 22 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2007 VOL 147 ISS 18
FILE LAST UPDATED: 21 Oct 2007 (20071021/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 4 L3
=> d 14 1-4 ibib abs hitstr

ACCESSION NUMBER: 2005:570896 CAPLUS

DOCUMENT NUMBER: 143:97390


TITLE: Preparation of pyrazolopyrimidinethione derivatives for treatment of impotence
INVENTOR(S): Li, Shuxin; Ren, Jianping; Zhao, Yanjin; Lv, Qiuju; Guo, Jinhua
PATENT ASSIGNEE(S): The Institute of Radiation Medicine, Academy of Military Medical Sciences P.R. China
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2005058899 | A1 | 20050630 | WO 2004-CN1312 | 20041118 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CN 1629163 | A | 20050622 | CN 2003-10118481 | 20031218 |
| EP 1695976 | A1 | 20060830 | EP 2004-797343 | 20041118 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| IN 2006MN00737 | A | 20070330 | IN 2006-MN737 | 20060623 |
| US 2007219220 | A1 | 20070920 | US 2007-583335 | 20070215 |
| PRIORITY APPN. INFO.: | | | CN 2003-10118481 | A 20031218 |
| | | | WO 2004-CN1312 | W 20041118 |

OTHER SOURCE(S): CASREACT 143:97390; MARPAT 143:97390
 GI




AB Title compds. represented by the formula I [wherein R1-R3 = independently ((cyclo)alkoxy)alkyl, alkenyl or aryl; R4 = alkyl, alkenyl, (cyclo)alkoxy, aryl; R5 = H, alkyl, alkenyl, (cyclo)alkoxy, aryl; R6 = H, (cyclo)alkyl, alkenyl, alkylcarbonyl; and pharmaceutically acceptable salts or solvates thereof] were prepared for treatment of impotence. For example, II was given in a multi-step synthesis starting from 4-amino-1-ethyl-3-propylpyrazole-5-carboxamide. I showed enhanced erectile response in rats similar to that of Sildenafil. Thus, I and their pharmaceutical compns. are useful for the treatment of impotence and sexlessness, having high selectivity over PDE V, long action time, less side reactions, and no side effects of blood pressure decreasing and heart rate increasing.

IT 856190-47-1 CAPLUS
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)

RN 856190-47-1 CAPLUS
CN Piperazine, 1-[(3-(1-ethyl-4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 856190-48-2P 856190-49-3P 856190-50-6P
 856190-51-7P 856190-56-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)


RN 856190-48-2 CAPLUS
CN Piperazine, 1-[(3-(1-ethyl-4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 856190-49-3 CAPLUS
CN Piperazine, 1-[(3-(1-ethyl-4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 856190-50-6 CAPLUS
CN Piperazine, 1-[(3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 856190-51-7 CAPLUS
CN Piperazine, 1-[(3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 856190-56-2 CAPLUS
CN Piperazine, 1-[(3-(1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 dipyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 856190-47-1
 CMF C23 H32 N6 O3 S2

Relative stereochemistry.




CM 2

CRN 77-92-9
 CMF C6 H8 O7




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2005:565628 CAPLUS
 DOCUMENT NUMBER: 143:211579
 TITLE: Low-energy collision-induced dissociation of sildenafil thione analogues: Gas-phase intramolecular nucleophilic substitution through ion-neutral complexes between a cationic substrate and a thione-containing neutral nucleophile
 AUTHOR(S): Lee, Jaekick; Yoo, Hye Hyun; Kang, Min-Yung; Kim, Dong-Hyun
 CORPORATE SOURCE: Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Seoul, S. Korea
 SOURCE: Rapid Communications in Mass Spectrometry (2005), 19(12), 1767-1770
 CODEN: RCMSEF; ISSN: 0951-4198
 PUBLISHER: John Wiley & Sons Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Collisional-activation mass spectrometry of sildenafil [i.e., 1-[(3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-(methyl)piperazine] and its thione analogs [e.g., 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-(methyl)piperazine] were reported.
 IT 479073-72-8 479073-74-0 479073-79-5
 479073-80-8 479073-86-4
 RL: PRP (Properties)
 ita (study of low energy collision-induced dissociation of sildenafil and thione analogs and study of gas-phase intramol. nucleophilic substitution through ion-neutral complexes between cationic substrate and thione-containing neutral nucleophile)
 RN 479073-72-8 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-74-0 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-79-5 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-80-8 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479073-86-4 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:524375 CAPLUS

DOCUMENT NUMBER: 141:420374

TITLE: Effects of a new selective phosphodiesterase type 5 inhibitor, KJH-1002, on the relaxation of rabbit corpus cavernosum tissue

AUTHOR(S): Cho, Eun Young; Chung, Sung-Hyun; Kim, Joong Hyup; Kim, Dong-Kyun; Jin, Changbae

CORPORATE SOURCE: Bioanalysis & Biotransformation Research Center, Korea

Institute of Science and Technology, Seoul, 130-650, S. Korea

SOURCE: 232-237 Journal of Applied Pharmacology (2003), 11(4),

PUBLISHER: CODEN: JCAPAG; ISSN: 1225-6110

DOCUMENT TYPE: Korean Society of Applied Pharmacology

LANGUAGE: English

AB The present study examined functional effects of a new selective phosphodiesterase type 5 inhibitor, 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-thioxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (KJH-1002), in the isolated rabbit corpus cavernosum (RCC). Relaxing effects of KJH-1002 were also compared with those of sildenafil, which is currently used as an oral therapy for penile erectile dysfunction. In the isolated RCC precontracted with phenylephrine, both KJH-1002 and sildenafil in the concentration range of 1 to 1000 nM,

produced a comparable potentiation of the elec. field stimulation-induced relaxation in a concentration-dependent manner. In the sodium nitroprusside (SNP)-induced

relaxation, the IC50 values, concns. of SNP required to produce a 50% relaxation of the phenylephrine-induced contraction, were significantly decreased to the similar extent by treatments with KJH-1002 and sildenafil. The results suggest that a new selective phosphodiesterase type 5 inhibitor, KJH-1002, has an augmentative effect on penile erection comparable to that of sildenafil and can be useful for the treatment of erectile dysfunction.

IT 479073-79-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KJH-1002 phosphodiesterase type-5 inhibitor produced relaxing effect on rabbit corpus cavernosum and showed augmentative effect on penile erection comparable to that of sildenafil and may be useful in

erectile dysfunction treatment)

RN 479073-79-5 CAPLUS

CN Piperazine,

1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2002:977816 CAPLUS

DOCUMENT NUMBER: 138:55978

TITLE: Preparation of novel pyrazolopyrimidinethiones as phosphodiesterase V inhibitors for treating erectile dysfunction

INVENTOR(S): Kim, Joong-Hyup; Kim, Youseung; Choi, Kyung Il; Kim, Dong Hyun; Nam, Ghilsoo; Seo, Jae Hong

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------------|-----------------|------------|
| WO 2002102802 | A1 | 20021227 | WO 2002-KR1126 | 20020614 |
| W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, U2, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| KR 2002095286 | A | 20021226 | KR 2001-33382 | 20010614 |
| AU 2002315822 | A1 | 20030102 | AU 2002-315822 | 20020614 |
| EP 1395593 | A1 | 20040310 | EP 2002-741455 | 20020614 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2005505509 | T | 20050224 | JP 2003-506275 | 20020614 |
| US 2004176371 | A1 | 20040909 | US 2003-480191 | 20031209 |
| PRIORITY APPLN. INFO.: | | | KR 2001-33382 | A 20010614 |
| | | WO 2002-KR1126 | | W 20020614 |

OTHER SOURCE(S): CASREACT 138:55978; MARPAT 138:55978
GI

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

AB The title compds. [I: R1, R2 = H, alkyl, cycloalkyl; R3 = alkyl, R4 = H, alkyl, cycloalkyl or alkenyl which is unsubstituted or substituted; X = O, NR4; substituted

with OH or alkoxy] which exhibit higher inhibitory activities against phosphodiesterase V as well as lower inhibitory activities against phosphodiesterase isoenzymes I, III and VI (biol. data given) and therefore are useful for the treatment of erectile dysfunction, were prepared E.g., a 3-step synthesis of I [R1 = Me; R2 = Pr; R3 = Et; X = NMe], starting from 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydropyrazolo[4,3-d]pyrimidin-7-one, which showed IC50 of 0.59 nM against PDE V, was given.

IT 479073-72-8P 479073-74-0P 479073-76-2P

479073-79-5P 479073-80-8P 479073-82-0P

479073-86-4P 479073-87-5P 479073-88-6P

479073-90-0P 479073-92-2P 479073-93-3P

479073-94-4P 479073-96-6P 479073-97-7P

479073-98-8P 479074-00-5P 479074-01-6P

479074-02-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazolopyrimidinethiones as PDE5 inhibitors for treating erectile dysfunction)

RN 479073-72-8 CAPLUS

CN Piperazine,


1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenylsulfonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-74-0 CAPLUS

CN Piperazine,


1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenylsulfonyl)-4-ethyl- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 479073-76-2 CAPLUS
 CN 1-Piperazineethanol, 4-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-79-5 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-80-8 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 479073-82-0 CAPLUS
 CN 1-Piperazineethanol, 4-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-86-4 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 479073-87-5 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphe nyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-88-6 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphe nyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 479073-90-0 CAPLUS
 CN 1-Piperazineethanol, 4-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphe nyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 479073-94-4 CAPLUS
 CN 1-Piperazineethanol, 4-[(4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-92-2 CAPLUS
 CN Piperazine, 1-[(4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 479073-96-6 CAPLUS


CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-93-3 CAPLUS
 CN Piperazine, 1-[(4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)

RN 479073-97-7 CAPLUS


CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 479073-98-8 CAPLUS
 CN 1-Piperazineethanol, 4-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 479074-00-5 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479074-01-6 CAPLUS
 CN Piperazine,
 1-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479074-02-7 CAPLUS
 CN 1-Piperazineethanol, 4-[(3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

```

=> log hold
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          27.19          200.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY          SESSION
CA SUBSCRIBER PRICE           -3.12          -3.12

```

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:51:56 ON 22 OCT 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/CAplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,